EVER Pharma Jena GmbH
PolandAll drugs from this manufacturer
-
The medicine is used in pregnant women (from 24 to 33 weeks of gestation) to delay preterm birth. It works by reducing the strength and frequency of uterine contractions.
Dosage form: solution for injection
Active substance Dosage atosiban 8.22 mg/ml ATC: G02CX01
-
The medicine is used in pregnant women (from 24 to 33 weeks of gestation) to delay preterm labor. It works by reducing the strength and frequency of uterine contractions.
Dosage form: solution for infusion, concentrate
Active substance Dosage atosiban 8.22 mg/ml ATC: G02CX01
-
The medicinal product is used in the treatment of multiple myeloma (a type of bone marrow cancer) in adults and in the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes).
Dosage form: solution for injection
Active substance Dosage bortezomib 2.5 mg/ml ATC: L01XG01
-
The medicine is used to treat prostate cancer when the disease progresses despite the use of other chemotherapy.
Dosage form: solution for infusion, concentrate
Active substance Dosage cabazitaxel 10 mg/ml ATC: L01CD04
-
The medicine is used in the treatment of Parkinson's disease. It helps to reduce the duration of "off" periods, i.e., periods of immobility in patients who were previously treated with levodopa or other dopamine agonists.
Dosage form: solution for infusion
Active substance Dosage apomorphine hydrochloride hemihydrate 5 mg/ml ATC: N04BC07
-
The medicinal product is used to provide sedation (a state of calmness, drowsiness, or sleep) in adult patients in intensive care units or during diagnostic procedures and treatments.
Dosage form: solution for infusion, concentrate
Active substance Dosage dexmedetomidine No input provided ATC: N05CM18
-
The medicine is used in the treatment of postmenopausal women with a certain type of breast cancer (estrogen receptor-positive) that is locally advanced or has metastasized. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg ATC: L02BA03
-
It is used for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and for the treatment of locally advanced or limited prostate cancer during or after radiotherapy.
Dosage form: implant
Active substance Dosage leuprorelin acetate 3.6 mg ATC: L02AE02
-
The medicine is used for the symptomatic treatment of advanced (hormone-dependent) prostate cancer and for the treatment of locally advanced or limited prostate cancer during or after radiotherapy.
Dosage form: implant
Active substance Dosage leuprorelin acetate 5 mg ATC: L02AE02
-
The medicine is used to treat severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis in children and adolescents, as well as severe psoriasis resistant to treatment and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 7.5 mg ATC: L04AX03
-
The medicine is used to treat severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis involving five or more joints in children and adolescents, as well as severe psoriasis resistant to treatment and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 10 mg ATC: L04AX03
-
The medicine is used to treat severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis in children and adolescents (when anti-inflammatory drugs are ineffective), as well as severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 12.5 mg ATC: L04AX03
-
The medicine is used to treat severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis (in patients for whom NSAIDs are ineffective), as well as severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 15 mg ATC: L04AX03
-
The medicine is used to treat severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis involving five or more joints in children and adolescents, as well as severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 17.5 mg ATC: L04AX03
-
The medicinal product is used for the treatment of severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis in children and adolescents, as well as for the treatment of severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 20 mg ATC: L04AX03
-
The medicinal product is used to treat severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis in children and adolescents, as well as the treatment of severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 22.5 mg ATC: L04AX03
-
The medicinal product is used for the treatment of severe active rheumatoid arthritis in adults, severe active juvenile idiopathic arthritis (in patients for whom NSAIDs are not sufficiently effective), as well as for the treatment of severe, treatment-resistant psoriasis and severe psoriatic arthritis in adults.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage methotrexate 25 mg ATC: L04AX03
-
The medicine is used to induce sedation (calming, drowsiness, or sleep) in adults and children during procedures, for anesthesia in adults, or as preparation for anesthesia.
Dosage form: solution for injection or infusion
Active substance Dosage midazolam hydrochloride 1 mg/ml ATC: N05CD08
-
The medicine is used in cancer therapy, specifically for the treatment of malignant pleural mesothelioma and advanced-stage lung cancer.
Dosage form: solution for infusion, concentrate
Active substance Dosage pemetrexed disodium 2.5-hydrate 30.2 mg/ml ATC: L01BA04
-
The medicine is used to treat bleeding from esophageal varices and in emergency cases of type 1 hepatorenal syndrome in patients with liver cirrhosis and ascites.
Dosage form: solution for injection
Active substance Dosage terlipressin acetate 0,2 mg/ml ATC: H01BA04
-
The medicine is used in adult men as replacement therapy in cases of testosterone deficiency (male hypogonadism). It helps to alleviate symptoms such as impotence, infertility, decreased libido, fatigue, depressive moods, or loss of bone mass.
Dosage form: solution for injection
Active substance Dosage testosterone enanthate 250 mg/ml ATC: G03BA03
-
The medicine is used in adult men as replacement therapy in cases of diseases resulting from testosterone deficiency (male hypogonadism), such as impotence, infertility, decreased libido, fatigue, depressive moods, or loss of bone mass.
Dosage form: solution for injection
Active substance Dosage testosterone undecanoate 1000 mg/4 ml ATC: G03BA03
-
The medicine is used to treat patients with advanced soft tissue sarcoma (when other medicines are ineffective or cannot be used) and to treat recurrent ovarian cancer.
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage trabectedin 0.25 mg ATC: L01CX01
-
The medicine is used to treat advanced soft tissue sarcoma (when other medicines are ineffective or cannot be used) and to treat recurrent ovarian cancer (in combination with another medicine called PLD).
Dosage form: powder for preparation of concentrate for infusion solution
Active substance Dosage trabectedin 1 mg ATC: L01CX01